Middle Age muScle Krill Study

Sarcopenia Clinical Trial

— MASK  

Official title:

The Effect of Krill Oil Supplementation on Muscle Function and Mass in Middle-aged Adults: A Randomised Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06005064
• Other study ID #: MASK
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2023
• Est. completion date: October 2024

Study information

• Verified date: November 2023
• Source: University of Glasgow
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will determine the effect of 6 months of supplementation with krill oil on muscle strength and mass in middle-aged adults. The study hypothesis is that krill oil supplementation will increase muscle strength and mass in middle-aged adults.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 92
• Est. completion date: October 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 60 Years

Eligibility

Inclusion Criteria:

• Be 35-60 years old
• Have a BMI of less than 35kg/m2

Exclusion Criteria:

• People with diabetes, severe cardiovascular disease, seizure disorders, uncontrolled hypertension (>150/90mmHg at baseline measurement), cancer or cancer that has been in remission <5 years, ambulatory impairments which would limit the ability to perform assessments of muscle function, dementia, on anticoagulant therapy, and/or taking medication known to affect muscle (e.g., steroids).
• People who have allergies to seafood, and/or regular consumption of more than 1 portion of oily fish per week.
• People who perform regular (>1 day/week) resistance exercise training.

Related Conditions & MeSH terms

• Sarcopenia

Intervention

Dietary Supplement:
• Krill oil
Superba krill oil
• Vegetable oil
Mixed vegetable oil

Locations

Country	Name	City	State
United Kingdom	University of Glasgow	Glasgow

Sponsors (1)

Lead Sponsor	Collaborator
University of Glasgow

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in systemic inflammation	Plasma levels of C-reactive protein, IL-1, IL-6, IL-8, IL-10, and TNF-a	Change from baseline to 24 weeks
Other	Change in muscle inflammation	Muscle total protein levels of TNF-a, IL-1ß, IL-6, IL-8, MCP-1 and total and phosphorylated levels of NF?B, JNK1/2 and STAT3	Change from baseline to 24 weeks
Other	Change in muscle anabolic signalling	Muscle total and phosphorylated protein levels of mTOR, IRS-1, Akt, 4EBP-1, p70S6K, RPS6, FOXO-1, GSK3ß and total protein levels of MAFBx and MURF-1	Change from baseline to 24 weeks
Primary	Change in knee extensor maximal isometric torque ( MVC)	Knee extensor maximal isometric torque measured during a maximal voluntary contraction	Change from baseline to 24 weeks
Secondary	Change in fat mass	Whole body fat mass measured by measured via bio-electrical impedance	Change from baseline to 24 weeks
Secondary	Change in lean mass	Whole body lean mass measured by measured via bio-electrical impedance	Change from baseline to 24 weeks
Secondary	Change in omega-3 levels	Red blood cell omega-3 levels	Change from baseline to 24 weeks
Secondary	Change in Grip strength	Grip strength measured with a hand held dynamometer	Change from baseline to 24 weeks
Secondary	Change in Muscle thickness	Vastus lateralis muscle thickness measured by ultrasound	Change from baseline to 24 weeks